Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Food Allergy
Conditions
Food Allergy
Trial Timeline
May 7, 2018 → Mar 10, 2020
NCT ID
NCT03463135About Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE is a phase 1 stage product being developed by Sanofi for Food Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT03463135. Target conditions include Food Allergy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03463135 | Phase 1 | Completed |
Competing Products
17 competing products in Food Allergy